Erythropoietin and rosuvastatin: comparative analysis of their cardioprotective actions in hearts subject to ischemia (IS)-reperfusion (RP)

MESTRE CORDERO, VICTORIA EVANGELINA; HERMANN R; D VELEZ; MOURGLIA JULIETA; JULIANA PEREGO; M.G MARINA PRENDES

Mar del Plata

Congreso; SAIC SAI SAFIS 2018; 2018

In previous work carried out in our laboratory we could show that Akt was involved, at least in part, in the direct cardioprotective effects of rosuvastatin (R,3uM). The aim of the present work was to investigate whether the Erythropoietin (E,2mU/ml), an Akt activator, promoted the same response as that exerted by R in the presence or absence of wortmannin (W,100nM), a PI3K/Akt inhibitor.Hearts from Wistar rats (200-250g) were subjected to 25 min of IS and 60 min of RP. E and W were added 10 and 15 min before global IS respectively. The contractility was evaluated by left ventricular developed pressure (LVDP), rate-pressure product (RPP), peak rate of contraction and peak rate of relaxation (±dP/dt) and left ventricular end-diastolic pressure (LVEDP). Tissue samples were taken to assess mitochondrial damage by electron microscopies and to evaluate infarct size. Mitochondria were isolated to evaluate the opening of mitochondrial permeability transition pore (MPTP) against different calcium concentrations. Infarct size was also measured by triphenyltetrazolium . ANOVA, (n=6/group).E improved the postischemic recovery of contractility in the same way as R, although LVDP presented a greater increase than developed by R (5 min RP, RPP(%): C:7±2, W:10±3, R:24±6*, R+W:9±3, E:24±3*, E+W:11±3, *p